GlassScriptPhysician profile
Leanne S Budde
NPI 1164415329
$2,812.64
in general payments reported to CMS, 2019-2025
40 companies · $617 in 2025
The $617 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.04 · 2020: $93.05 · 2021: $86.54 · 2022: $644 · 2023: $669 · 2024: $670 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673 · Consulting Fee: $250 · Education: $33.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.86 |
| Consulting Fee | $250.00 |
| Education | $33.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $436.82 | 2022-2025 | |
| Tempus Ai, INC | $250.00 | 2024 | |
| Genzyme Corporation | $200.51 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $171.91 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $168.49 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Celgene Corporation | $128.55 | 2021-2023 | Pomalyst, Reblozyl |
| Galvanize Therapeutics, INC | $116.19 | 2023 | Aliya System |
| Amgen INC. | $112.41 | 2020-2023 | Lumakras |
| Daiichi Sankyo INC. | $105.61 | 2022-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $104.69 | 2021-2025 | Libtayo |
| Eisai INC. | $84.78 | 2022-2025 | |
| Pfizer INC. | $77.74 | 2022-2025 | |
| Gilead Sciences, INC. | $77.50 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $71.34 | 2019-2023 | Lynparza, Keytruda |
| Aveo Pharmaceuticals, INC. | $59.55 | 2022-2025 | Fotivda |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Budde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.